BLPH NASDAQ
Bellerophon Therapeutics, Inc.
1W: +20.0%
1M: -68.4%
3M: -65.7%
1Y: -62.9%
3Y: -99.5%
5Y: -99.8%
$0.01
Last traded 2024-12-18 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$65K
+36.3% ▲
Operating Income
-$22M
-11.0% ▼
Net Income
-$20M
-11.7% ▼
EPS (Diluted)
$-2.08
-11.2% ▼
EBITDA
-$22M
-14.0% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $362K | $348K | $147K | $102K | $65K |
| Gross Profit | -$362K | -$348K | -$147K | -$102K | -$65K |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $20M | $11M | $18M | $13M | $16M |
| SG&A Expenses | $8M | $6M | $8M | $7M | $6M |
| Operating Expenses | $28M | $17M | $26M | $20M | $22M |
| Operating Income | -$28M | -$17M | -$26M | -$20M | -$22M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $0 | $250K | $5K | $135K |
| Income Before Tax | -$3M | -$15M | -$27M | -$20M | -$22M |
| Tax Expense | -$5M | -$2M | -$2M | -$2M | -$2M |
| Net Income | $3M | -$13M | -$25M | -$18M | -$20M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $0.65 | $-2.95 | $-3.17 | $-1.87 | $-2.08 |
| EBITDA | -$2M | -$15M | -$27M | -$19M | -$22M |
| Shares Outstanding | 4M | 5M | 8M | 10M | 10M |